Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.665
-0.125 (-3.30%)
Oct 29, 2025, 3:19 PM EDT - Market open
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $836.00K in the quarter ending June 30, 2025, with 7.46% growth. This brings the company's revenue in the last twelve months to $2.94M, up 41.61% year-over-year. In the year 2024, Orchestra BioMed Holdings had annual revenue of $2.64M, down -4.42%.
Revenue (ttm)
$2.94M
Revenue Growth
+41.61%
P/S Ratio
49.03
Revenue / Employee
$42,057
Employees
70
Market Cap
197.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
| Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
| Dec 31, 2022 | 3.53M | 4.32M | -551.79% |
| Dec 31, 2021 | -782.00K | -6.49M | -113.71% |
| Dec 31, 2020 | 5.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
OBIO News
- 1 day ago - Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements - GlobeNewsWire
- 2 days ago - Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial - GlobeNewsWire
- 20 days ago - Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit - GlobeNewsWire
- 7 weeks ago - Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction - GlobeNewsWire
- 2 months ago - Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility - GlobeNewsWire